Latest news about Lincoln Pharmaceuticals
Lincoln Pharmaceuticals
734.15
+2.00(+0.27%)
Company Performance:
View Company Insights1D+0.27%
1M+20.72%
6M+38.75%
1Y+21.24%
5Y+124.27%
More news about Lincoln Pharmaceuticals
18Feb 26
Lincoln Pharmaceuticals Makes Q3FY26 Conference Call Recording Available
Lincoln Pharmaceuticals has fulfilled regulatory requirements by making available the audio recording of its Q3FY26 results conference call held on February 18, 2026. This follows the company's impressive quarterly performance showing 37.70% YoY net profit growth to ₹28.60 crore and 13.49% revenue growth to ₹166.32 crore.
10Jan 26
Lincoln Pharmaceuticals Receives CRISIL Credit Rating Reaffirmation at A/Stable for Long-term Facilities
Lincoln Pharmaceuticals Limited received credit rating reaffirmation from CRISIL Limited on January 09, 2026, with long-term bank facilities maintained at CRISIL A/Stable and short-term facilities at CRISIL A1. The ratings cover total bank facilities of ₹102.00 crore and reflect the company's established market position, promoter experience, and healthy financial profile with ₹671.00 crore networth against nil debt. Revenue grew 14.00% to ₹623.23 crore in fiscal 2025, though working capital intensity and regulatory risks remain areas of concern.
07Aug 25
Lincoln Pharma Reports 17% Net Profit Growth in Q1, Targets ₹1,000 Crore Revenue in 3 Years
Lincoln Pharmaceuticals reported strong Q1 FY26 results with a 17% increase in net profit to ₹27.70 crore and a 7.3% rise in total income to ₹169.34 crore. EBITDA grew by 17.92% to ₹39.08 crore. The company aims to achieve ₹1,000 crore in revenue within three years, targeting 15-18% annual growth. Lincoln Pharma launched a bulk drug manufacturing plant and received approvals for 10 products. The company's shares closed at ₹576.90 on BSE, up 8.47%.
07Aug 25
Lincoln Pharmaceuticals Reports 16.93% Profit Growth in Q1, Reappoints Key Directors
Lincoln Pharmaceuticals reported a 16.93% year-on-year increase in Q1 net profit to Rs. 27.70 crore. Total income rose by 7.39% to Rs. 169.34 crore, while EBITDA grew 17.92% to Rs. 39.08 crore. The company re-appointed key leadership positions, including Mahendra G. Patel as Managing Director. Lincoln aims to achieve Rs. 1,000 crore revenue within three years, targeting 15-18% annual growth. The company plans to expand its global presence from 60+ to 90 countries in 2-3 years. FII stake in the company increased from 3.95% to 5.13% over the past year.
02Jul 25
Lincoln Pharmaceuticals Completes Trial Run at Khatraj Facility, Eyes API Production
Lincoln Pharmaceuticals has successfully completed the trial run of its Khatraj facility, a key step in its expansion plans. The company aims to commence commercial production of Active Pharmaceutical Ingredients (APIs) at this facility within 1-2 years, subject to regulatory approvals. This move is expected to enhance manufacturing capabilities, potentially leading to vertical integration, cost efficiency, improved quality control, and stronger market positioning.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Zydus Life Science
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,844.60
(-2.47%)
6,887.00
(+0.42%)
4,486.20
(+0.38%)
1,399.20
(-0.19%)
1,307.20
(-0.86%)
1,038.95
(+0.24%)
2,281.80
(-0.12%)
2,479.40
(-1.38%)
1,463.50
(-5.38%)
1,343.50
(-0.56%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
